About the Bionics Institute


Bionics Institute Research Online >
Bionic Hearing >
Bionic Hearing Research Publications >

Title: Neurotrophin gene therapy for sustained neural preservation after deafness
Authors: Atkinson, Patrick
Wise, Andrew
Flynn, Brianna
Nayagam, Bryony
Hume, Clifford
O'Leary, Stephen
Shepherd, Robert
Richardson, Rachael
Keywords: Brain-Derived Neurotrophic Factor - therapeutic use
Cochlear Implantation
Cochlear Nerve - drug effects
Cochlear Nerve - pathology
Deafness - drug therapy
Deafness - pathology
Neurons - drug effects
Neurons - pathology
Adenoviridae - genetics
Brain-Derived Neurotrophic Factor - genetics
Cell Survival
Gene Expression
Genetic Therapy - methods
Genetic Vectors
Neurotrophin 3 - genetics
Neurotrophin 3 - therapeutic use
Recombinant Proteins - therapeutic use
Recombinant Proteins - genetics
Spiral Ganglion - physiopathology
Issue Date: 17-Dec-2012
Publisher: PLOS
Citation: Atkinson, P., Wise, A., Flynn, B. O., Nayagam, B. A., Hume, C., O'Leary, S., Shepherd, R., & Richardson, R. (2012). Neurotrophin gene therapy for sustained neural preservation after deafness. PLOS One, 7(12), e52338.
Abstract: The cochlear implant provides auditory cues to profoundly deaf patients by electrically stimulating the residual spiral ganglion neurons. These neurons, however, undergo progressive degeneration after hearing loss, marked initially by peripheral fibre retraction and ultimately culminating in cell death. This research aims to use gene therapy techniques to both hold and reverse this degeneration by providing a sustained and localised source of neurotrophins to the deafened cochlea. Adenoviral vectors containing green fluorescent protein, with or without neurotrophin-3 and brain derived neurotrophic factor, were injected into the lower basal turn of scala media of guinea pigs ototoxically deafened one week prior to intervention. This single injection resulted in localised and sustained gene expression, principally in the supporting cells within the organ of Corti. Guinea pigs treated with adenoviral neurotrophin-gene therapy had greater neuronal survival compared to contralateral non-treated cochleae when examined at 7 and 11 weeks post injection. Moreover; there was evidence of directed peripheral fibre regrowth towards cells expressing neurotrophin genes after both treatment periods. These data suggest that neurotrophin-gene therapy can provide sustained protection of spiral ganglion neurons and peripheral fibres after hearing loss.
URI: http://repository.bionicsinstitute.org:8080/handle/123456789/26
ISSN: 1932-6203
Appears in Collections:Bionic Hearing Research Publications

Files in This Item:

File Description SizeFormat
2012-Atkinson_Neurotrophin.pdf1.58 MBAdobe PDFView/Open
View Statistics

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


DSpace Software Copyright © 2002-2010  Duraspace -